Melbourne, AustraliaFounded 201835+ employeesPrivate
$19.7M raisedSeries A· last: series a (Mar 2023)· 4 rounds
Backed by(22 investors)
We help healthcare providers treat their gastrointestinal patients with AI-delivered therapy. Using machine learning and large language models, we learn from therapy data, outcomes, and physiology to deliver adaptive, scalable treatments for conditions like IBS - without the waitlist.
